Sarcopenia is the one age-related condition with a treatment that unambiguously works, is available to everyone, and cannot be bought. That is an awkward message for a field that would rather sell a molecule, and it is why the topic attracts so much noise. What follows is the evidence hierarchy as it actually stands: what the condition is defined as now, what has high-quality evidence behind it, what has modest evidence, and what is still investigational.
The definition changed, and it matters
For years sarcopenia meant “low muscle mass,” which sent both research and consumer products chasing the wrong number. In 2019 the European Working Group on Sarcopenia in Older People published a revised consensus that reorganized the whole diagnosis: it focuses on low muscle strength as the key characteristic, uses low muscle quantity and quality to confirm the diagnosis, and identifies poor physical performance as indicative of severe sarcopenia.[1]
The consensus also frames sarcopenia as a muscle disease — muscle failure — rooted in adverse muscle changes accruing across a lifetime, common in older adults but capable of starting much earlier. The practical consequence for anyone reading their own results: a body-composition scan showing adequate lean mass does not rule it out, and a grip-strength measurement is closer to the actual definition than a DEXA printout.
What has high-quality evidence: resistance training
A systematic umbrella review commissioned to inform clinical guidelines examined 14 systematic reviews and meta-analyses across four exercise categories — resistance training, resistance training plus nutritional supplementation, multimodal exercise programs and blood-flow-restriction training. Its conclusion on the first was unambiguous: there is high-quality evidence for a positive and significant effect of resistance training on muscle mass, muscle strength and physical performance.[2]
The same review delivered the finding that most supplement marketing omits: the added effect of nutritional supplementation on top of resistance training appears limited where muscle function is concerned.[2]Supplementation is not useless — see the protein data below — but it is an adjunct to the stimulus, not a substitute for it.
| Intervention | Evidence quality | What it does |
|---|---|---|
| Resistance training | High | Improves muscle mass, muscle strength and physical performance |
| Protein supplementation with training | Moderate | Adds ~0.30 kg fat-free mass and ~2.49 kg 1RM; effect declines with age |
| Nutritional supplementation added to training | Limited for muscle function | Smaller additive effect than commonly claimed |
| Pharmacological agents | Investigational | None approved for sarcopenia; candidates studied for muscle preservation in obesity trials |
Protein: real, dose-limited, and less effective with age
The protein question has a good answer. A systematic review, meta-analysis and meta-regression of 49 studies with 1,863 participants found that protein supplementation significantly augmented resistance-training gains: one-repetition maximum strength rose by 2.49 kg and fat-free mass by 0.30 kg beyond training alone.[3]
Two qualifiers do most of the practical work. The effect on fat-free mass was reduced with increasing age — precisely the population most interested in it. And protein supplementation beyond a total intake of about 1.62 g/kg/day produced no further training-induced gains in fat-free mass.[3] That number is the ceiling worth knowing: it converts a marketing question into an arithmetic one, and for most people the answer is that they are already close to it or can get there with food.
The drug pipeline, honestly described
No pharmacological agent is approved to treat sarcopenia. The most advanced work targets the myostatin–activin pathway, and it is being tested in obesity rather than in sarcopenia. In a phase 2 trial of 507 adults with obesity, bimagrumab — an investigational antibody against type II activin receptors — produced a mean weight change at 48 weeks of −9.3 kg on its own, against −14.2 kg for semaglutide 2.4 mg and −17.8 kg for the high-dose combination, versus −3.3 kg on placebo. Common adverse events with bimagrumab included muscle spasms, diarrhea and acne.[4]
Read that carefully: it is a body-weight trial in obesity, not a sarcopenia trial in older adults, and the drug is investigational. It is here because it is the clearest signal that muscle-directed pharmacology is being taken seriously — not because it is an option today. We track the compound separately in the bimagrumab evidence review.
The supplement shelf adjacent to this topic is long and mostly thin. The two ingredients with the least speculative cases are creatine and HMB; the growth-hormone-axis peptides sold for “muscle preservation” are a different proposition entirely, assessed in growth hormone secretagogues and peptides for muscle growth. Testosterone is its own conversation, covered in the TRT evidence review.
The honest bottom line
Sarcopenia is now defined by strength rather than size, and the treatment with high-quality evidence behind it is resistance training — not a supplement stack, not a peptide, not yet a drug. Protein helps at the margin, up to roughly 1.62 g/kg/day, and helps less as you get older, which is an argument for starting earlier rather than dosing higher. Everything pharmacological in this space is still investigational, and the trials that exist were designed to answer a different question.